FERVESCENCE COMPOSITION

Abstract: This invention provides a fervescence composition containing 15-keto-PGEs separated from any substantial activity such as decrease of blood pressure.

Description: This invention relates to the manufacture of a medicament for increasing body temperature. Such medicaments are referred to herein as fervescence compositions. Development of a drug for recovering from hypothermia occurring after hypothermic operation such as operation of cardiovasculum and brain surgery, hypothermia caused by a decline of basal metabolism such as thyroid hormone hyposecretion, hypothermia by disorder of the brain or hypothermia caused by serious bleeding and disorder of consciousness caused by, for example, a traffic accident as well as development of a drug for preventing from hypothermia have been desired. On the other hand, prostaglandins are known to have various pharmacological activities, such as antiplatelet aggregation activity, myometrium stimulating activity, and antiulcer activity. Among prostaglandins, for example, prostaglandin E₂ is known to have fervescence activity. However, it cannot be used as a drug for restoring body temperature since it strongly decreases the blood pressure at the same time. On the other hand, 15-keto-prostaglandin E (noted as 15-keto-PGE hereafter) and 13,14-dihydro-15-keto-prostaglandin E (noted as 13,14-dihydro-15-keto-PGE hereinafter) are known as substances naturally produced by an enzyme in the metabolism of prostaglandin E (noted as PGE hereinafter) in a living body. These 15-keto-PGE have been considered to be physiologically and pharmacologically inactive substances (Acta Physiologica Scandinavica, Vol. 66, pp509 (1966). It has never been recognized that these 15-keto-PGE compounds have fervescence activity. According to the present invention there is provided the use of 15-keto-PGEs for the manufacture of a medicament for increasing body temperature. The medicament may be used, for example, for restoring body temperature or for the treatment of hypothermia. The invention thus relates to fervescence compositions containing 15-keto-prostaglandin E or their derivatives, which do not have any substantial activity such as decrease of blood pressure. The term 15-keto-PGE as used hereinafter includes 15-keto-PGE derivatives. In this invention, 15-keto-PGEs include 15-keto-PGEs of which the carbon atom of the 15-position is carbonyl, and 13,14-dihydro-15-keto-PGEs of which the bond between carbon atoms of the 13- and 14-position is saturated and the carbon atom of the 15-position is carbonyl. Therefore, this invention includes every prostaglandin E as long as it is in 15-keto or 13,14-dihydro-15-keto form in the prostaglandin skeleton structure and is not limited by other additional skeleton structure or substituents. In the present specification 15-keto-PGEs are expressed according to the following nomenclature. The 15-keto-PGEs have a following basic structure: and the position number of carbon atom constituting α-chain, ω-chain and five member ring in the prostaglandin skeleton structure is used as it is in the nomenclature. That is, the position number of the carbon atom in the skeleton structure is started from the carbon atom constituting carboxylic acid of the terminal position of α-chain through the five members ring to ω-chain i.e. 1 to 7 are attached to the carbon atoms in the α-chain in this order, 8 - 12 are attached to the carbon atoms in the five members ring, and 13 - 20 are attached to the carbon atoms in the ω-chain. In the compound whose carbon number in α-chain is less than 7 the position number is simply eliminated from 2 to 7 in this order without any change of the position number of the other carbons. In other word 15-keto-PGEs having 6 carbon atoms in the α-chain have no position of 2, i.e. 15-keto-PGEs of such compound are not renamed as 14-keto-PGEs. In case that carbon atoms increase in the α-chain the carbon chain increased is nominated as a substituent on the carbon of position number 2 without any change of the position number of the other carbons. Therefore, 15-keto-PGEs having 8 carbon atoms in the α-chain are named as 15-keto-2-decarboxy-2-acetic acid-PGEs. When the number of carbons in the ω-chain decreases the position number is named by reducing it from the carbon of position number 20 one by one. When the number of the carbon atoms in the ω-chain increases, the increased carbon chain is named as a substituent on the carbon of position number 20. That is, 15-keto-PGEs having 10 carbon atoms in the ω-chain are named as 15-keto-20-ethyl-PGEs. All configurations of 15-keto-PGEs described in this specification are as in the above formula. 15-keto-PGEs have a hydroxy group on the carbon atom at the 11-position in general, but in the present specification term "15-keto-PGEs" includes prostaglandins having other group instead of said hydroxyl group of normal PGE. Such PGEs are called as 11-dehydroxy-11-substituent-PGEs, for instance, 11-dehydroxy-11-methyl-PGEs in case of the substituent being a methyl group. PGEs are classified as 15-keto-PGE₁ and 15-keto-PGE₂ according to the bonds between carbon atoms of the 5, 6 and 7 positions. 15-keto-PGE₁ and its derivatives (referred to as PGE₁s hereinafter) are named as a group of compounds in which the bond between carbon atoms of 5 and 6 position, and of 6 and 7 position are a single bond respectively. PGE₂ and its derivatives (referred to as PGE₂s hereinafter) are called to a group of compounds in which the bond between carbon atoms of 5 and 6 position is a trans-double bond. Therefore, PGEs having a structure of are named as 6-keto-PGE₁s, and PGEs having a structure of are called 5,6-dehydro-PGE₂s. The fervescence activity is remarkably expressed in 15-keto-PGEs represented by the following formula: wherein R is a hydroxyl group, a hydroxyalkyl group, or an alkyl group; Y is a saturated or unsaturated hydrocarbon moiety having 2 - 6 carbon atoms wherein a portion of carbon atoms constituting the hydrocarbon moiety may be carbonyl or a portion of hydrogen atoms constituting the hydrocarbon moiety may be substituted with other atoms or groups; Z is a saturated or unsaturated hydrocarbon moiety which may constitute a straight chain or a ring, wherein a portion of hydrogen atoms of the hydrocarbon moiety may be substituted with other atoms or groups; or physiologically acceptable salts thereof or esters which are esterified on the terminal carboxyl group. Y represents a saturated or an unsaturated hydrocarbon moiety having 2 - 6 carbon atoms, including an aliphatic hydrocarbon such as an alkyl group, an alkenyl group, and an alkynyl group. Y may preferably be hydrocarbon chain having 6 carbon atoms. Examples of PGEs of which Y is an unsaturated hydrocarbon moiety are PGE₂s, 5,6-dehydro-PGE₂s, and PGEs of which the bond between 2- and 3-position is unsaturated. A portion of carbon atoms constituting hydrocarbon moiety represented by Y may be carbonyl, for example 6-keto-PGE₁s in which the carbon atom of 6-position is a carbonyl. The hydrocarbon moiety represented by Y may be substituted with atoms or groups selected from halogen atoms such as a fluorine atom, a chlorine atom, typically a fluorine atom; an alkyl group such as methyl, ethyl; a hydroxyl group. Typical examples of such substituents are 15-keto-PGEs having an alkyl group on the carbon atom at the 3-position. Z represents a saturated or an unsaturated hydrocarbon moiety having 1 - 10 carbon atoms. The hydrocarbon moiety may be an aliphatic hydrocarbon or a cyclic hydrocarbon itself or in part. The hydrocarbon moiety represented by Z may be substituted with other atoms or groups. The number of the carbon atoms of Z is preferably 3 - 7 in a straight chain. PGEs of which carbon numbers of Z are 5 correspond to typical PGEs. Therefore, the PGEs of which carbon numbers of the hydrocarbon moiety represented by Z are 6 or more than 6 are regarded as PGEs having a substituent on the carbon atom of 20-position. That is, PGEs of which the number of carbon atoms of Z is 6 are named as 20-methyl-PGEs. Though the hydrocarbon moiety represented by Z may have substituents at any position, a saturated hydrocarbon is more preferable. Examples of the hydrocarbon moiety having a cyclic ring are cyclopentyl or cyclohexyl containing the carbon atom of 16- or 17-position itself as a ring constituting member. The hydrocarbon moiety represented by Z may be substituted with atoms or groups selected from halogen atoms such as a fluorine atom or a chlorine atom; an alkyl group such as methyl, ethyl, isopropyl, isopropenyl; an alkoxy group such as methoxy, ethoxy; a hydroxyl group; a phenyl group; a phenoxy group. The position of the substituent may be preferably the carbon atom at the 16-, 17-, 19- and/or at the 20-position, but it is not restricted. Examples of preferable compounds include one which has one or two, different or identical atom(s) and/or groups, for example, halogen atoms such as a fluorine atom; an alkyl group such as methyl, ethyl; an aromatic group which may have substituent such as phenyl, benzyl, phenoxy; a hydroxyl group on the carbon atom at the 16-position. Other examples of preferable compounds include one which has a cycloalkyl group such as cyclopentyl, cyclohexyl which contains the carbon atom at the 16-position as a constituent of the cyclic ring; an alkyl group such as methyl, ethyl on carbon atom of 17- or 19-position; an alkyl group such as methyl, ethyl, isopropyl, isopropenyl; an alkoxy group such as methoxy, ethoxy, propoxy on the carbon atom at the 20-position. A generic name of PGEs is used for compounds having a prostanoic acid structure in which the carbon atom of 11-position has a hydroxyl group, and the carbon atom of 9-position is carbonyl. In the present specification a prostanoic acid compound in which the hydroxyl group on the carbon atom at the 11-position is substituted with a hydroxyalkyl group or an alkyl group is also called PGEs. Therefore, the 15-keto-PGEs of the present invention include compounds in which R of the general formula (I) represents a hydroxyalkyl group or an alkyl group, for example, a hydroxy group such as hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-methyl-1-hydroxyethyl; an alkyl group such as methyl, ethyl. The steric configuration of R with respect to the carbon at the 11-position may be α or β or mixture thereof. The 15-keto-PGEs of the present invention may be a physiologically acceptable salt or ester which is esterified on the terminal carboxyl group. The cation to be used for producing such salts may be an alkaline metal such as sodium and potassium; an alkaline earth metal such as calcium or magnesium; amines such as methylamine, dimethylamine, cyclopentylamine, benzylamine, piperidine, monoethanolamine, diethanolamine, monomethylmonoethanolamine, tromethamine, lysine, ammonium, and tetraalkylammonium salts. Useful esters of 15-keto-PGEs may include a saturated or an unsaturated lower alkyl ester which may have a branched chain such as methyl, ethyl, propyl, n-butyl, isopropyl, t-butyl, 2-ethylhexl, and allyl; an aliphatic cyclic ester such as cyclopropyl, cyclopentyl, and cyclohexyl; an aromatic ester which may have substituents such as benzyl, and phenyl; a hydroxyalkyl or an alkoxyalkyl ester such as hydroxyethyl, hydroxyisopropyl, methoxyethyl, ethoxyethyl, and methoxyisopropyl; a trialkylsilyl ester such as trimethylsilyl, and triethylsilyl; a heterocyclic ester such as tetrahydropyranyl. Preferable esters for the present invention are lower alkyl esters which may have a branched chain, for instance, methyl, ethyl, propyl, n-butyl, isopropyl, t-butyl; a benzyl ester; and a hydroxyalkyl esters such as hydroxyethyl, hydroxy isopropyl;. 15-keto-PGEs of the present invention may include various kinds of isomers such as tautomeric isomers, optical isomers, and geometric isomers. For example a tautomeric isomer between the hydroxyl group at carbon atom at the 11-position and the carbonyl group on carbon atom at the 15-position of 15-keto-PGEs. The latter tautomeric isomer is likely in 15-keto-PGEs having an electron attractive group such as fluorine atom at 16-position. A hemiacetal, a tautomeric isomer between the hydroxyl group at carbon atom at the 11-position and the carbonyl group on carbon atom at the 15-position, may be formed, and an equilibrium mixture of the compound of R being a hydroxyl group and a hemiacetal may be given. Such an equilibrium mixture or the tautomeric isomer is also included in the 15-keto-PGEs of the present invention. The most preferred group of 15-keto-PGEs of the present invention are 15-keto-PGEs having a double bond between carbon atoms at the and 6-position or forming carbonyl group at the 6-position. Another preferred group of 15-keto-PGEs of the present invention is one having 8 - 10 carbon atoms in the ω-chain. Another preferable group of 15-keto-PGEs of the present invention is one which has (a) halogen atom(s) or (an) alkyl substituents at the 16-position. Another preferred one includes 15-keto-PGEs which have a lower alkyl, especially methyl substituent at the 19-position of ω-chain having carbon atoms of more than 7 in the skeleton chain. Examples of most preferable 15-keto-PGEs are 13,14-dihydro-15-keto-19-methyl-PGE₂ alkyl ester, 13,14-dihydro-15-keto-16R,S-fluoro-PGE₂ alkyl ester, 13,14-dihydro-15-keto-16R,S-fluoro-11-dehydroxy-11R-methyl-PGE₂ alkyl ester, 13,14-dihydro-15-keto-20-methyl-PGE₂ alkyl ester, 13,14-dihydro-15-keto-16R,S-methyl-PGE₂ alkyl ester, 13,14-dihydro-6,15-diketo-19-methyl-PGE₁ alkyl ester, 13,14-dihydro-6,15-diketo-16R,S-fluoro-PGE₁ alkyl ester, 13,14-dihydro-6,15-diketo-16R,S-fluoro-11-dehydroxy-11R-methyl-PGE₁ alkyl ester, 13,14-dihydro-6,15-diketo-20-methyl-PGE₁ alkyl ester and 13,14-dihydro-6,15-diketo-16R,S-methyl-PGE₁ alkyl ester. In the present specification PGEs are named based on a prostanoic acid skeleton, but it can be named according to IUPAC nomenclature, according to which, for instance, PGE, is named as 7-{(1R,2R,3R)-3-hydroxy-2-[(E)-(3S)-3-hydroxy-1-actenyl]-5-oxo-cyclopentyl}-heptanoic acid; PGE₂ is named as (Z)-7-{(1R,2R,3R,)-3-hydroxy-2-[(E)-(3S)-3-hydroxy-1-octenyl]-5-oxo-cyclopentyl}-hept-5-enoic acid; 13,14-dihydro-15-keto-16R,S-fluoro-PGE₂ is named as (Z)-7-{(1R,2R,3R)-3-hydroxy-2-[(4R,4S)-4-fluoro-3-oxo-1-octyl]-5-oxo-cyclopentyl}-hept-5-enoic acid; 13,14-dihydro-15-keto-20-ethyl-11-dehydroxy-11R-methyl PGE₂ methyl ester is named as Methl 7-{(1R,2S,3R)-3-methyl-2-[3-oxo-1-decyl]-5-oxo-cyclopentyl}-kept-5-enoate; and 13,14-dihydro-6,15-diketo-19-methyl-PGE₂ ethyl ester is named as Ethyl 7-{(1R,2R,3R)-3-hydroxy-2-(7-methyl-3-oxo-1-octyl)-5-oxo-cyclopentyl}-6-oxo-heptanoate. The 15-keto-PGEs show fevescence activity after intracerebroventricular administration when carboxylic acid type compounds or carboxy ester type compounds are used. However, the carboxylic acid type compounds show no fervescence activity by peripheral administration such as intravenous injection or oral administration. On the other hand, carboxy ester type compounds show fervescence activity even when administered peripherally such as intravenously and orally. The ester compound of which R is a lower alkyl group such as methyl or ethyl group shows strongest fevescence activity. The 15-keto-PGEs are effective to produce an improvement in body mechanism in an animal which is out of homeostasis (normal condition) or under anaesthesia or in shock by bleeding. The 15-keto-PGEs used in this invention may be prepared, for example, by the method noted in Japanese Patent Application No. 18326/1988. A practical preparation of the 13,14-dihydro-15-keto PGEs involves the following steps; as shown in the synthetic chart (I), reaction of the aldehyde (2) prepared by the Colins oxidation of commercially available Corey lactone (1) with dimethyl (2-oxoheptyl)phosphate anion to give α,β-unsaturated ketone (3), reaction of the α,β-unsaturated keton (3) to the corresponding saturated ketone (4), protection of the carbonyl group of the ketone (4) with a diol to the corresponding ketal (5), and deprotection of the p-phenylbenzoyl group to give the corresponding alcohol (6) followed by protection of the newly generated hydroxy group with dihydropyrane to give the corresponding tetrapyranyl ether (7). According to the above process, a precursor of PGEs of which ω chain is a 13,14-dihydro-15-keto-alkyl group is prepared. Using the above tetrapyranyl ether (7), 6-keto-PGE₁s (15) a group constituted with carbon atoms at the 5-, 6- and 7-position is may be prepared in the following steps; reduction of the tetrapyranyl ether (7) with, for example, diisobutyl aluminum hydride to give the corresponding lactol (8), reaction of the lactol (8), with the ylide generated from (4-carboxybutyl)triphenyl phosphonium bromide followed by esterification, cyclization between the double bond between at carbon atoms of 5- and 6-position and the hydroxyl group on carbon atom at the 9-position with NBS or iodine to give the halogenated compound (11), dehalogenation of the compound (11) with, for example, DBU to give the 6-keto compound (13) followed by Jhones oxidation and removal of the protecting groups. Furthermore, PGE₂s (19) of which a group constituted with carbon atoms at the 5-,6- and 7-position is may be prepared in the following steps; as shown in the synthetic chart II, reduction of the above the tetrapyranyl ether (7) to give the lactol (8), reaction of the resultant lactol (8) with the ylide generated from (4-carboxybutyl)triphenyl phosphonium bromide to give the carboxylic acid (16) followed by esterification of (17), Jhones oxidation of the esters (17) to give the compound (18), and removal of the protecting groups. Using the above the tetrapyranyl ether (7) as starting material, the compound having the group of may be prepared by using the same process for preparing PGE₂s having the group of and applying the resultant compound (18) to catalytic reduction for reducing the double bond between at the 5- and 6-position followed by removal of the protection groups. Synthesis of 5,6-dehydro-PGE₂s having a group of may be carried out by alkylation of the resulting a copper enolate generated after 1,4-addition of a monoalkylcopper complex or a dialkylcopper complex of the following formula: to 4R-t-butyldimethylsilyloxy-2-cyclopenten-1-one with 6-alkoxycarbonyl-1-iodo-2-hexyne or the derivatives. The 11-β type PGEs can be prepared according to the synthetic chart III. The 15-keto-PGEs of this invention may be used as a medicine for animals and human beings and usually applied systemically or locally by the method of oral administration, oral administration by spraying, intravenous injection (including instillation), subcutaneous injection, or suppository. Dose is determined depending on the animal to be treated, the human patient, age, body weight, symptom, therapeutic effect, administration route, and treatment time, but is preferably 0.001 - 500 mg/Kg. As solid composition of this invention for oral administration, tablets, powders and granules are included. The solid composition containing one or more active substances is mixed with at least one inactive diluent such as lactose, mannitol, glucose, hydroxypropyl cellulose, fine crystalline cellulose, starch, polyvinyl pyrolidone, magnesium aluminate metasilicate. The composition may contain apart from the inactive diluent other additives such as lubricants (e.g. magnesium stearate), a disintegrator (e.g. cellulose calcium gluconate), a stabilizer (e.g. α-, β - or γ-cyclodextrin, etherated dextrin (e.g. dimethyl-α-, dimethyl-β-, trimethyl-β- or hydroxypropyl-β-cyclodextrin), branched cyclodextrin (e.g. glucosyl- or maltosylcyclodextrin), formyl cyclodextrin, sulfur-containing cyclodextrin or misoprotol). Such cyclodextrins may form an inclusion compound with 15-keto-PGEs in some cases to increase the stability of the compounds. The stability may be often increased by forming lyposomes with a phospholipid. Tablets and pills may be coated with an enteric or gastroenteric film such as white sugar, gelatin, hydroxypropylcellulose, and hydroxypropylmethylcellulose phthalate, if necessary, they may be covered with two or more layers. Additionally, the composition may be in the form of capsules made of a substance easily absorbed such as gelatin. Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs and contain a generally used inactive diluent such as purified water or ethyl alcohol. The composition may contain additives such as wetting agents and suspending agents as well as sweeteners, flavors, aromatics and preservatives. The compositions for oral administration may contain one or more active substances. The injection of this invention for non-oral administration includes sterile aqueous or nonaqueous solutions, suspensions, and emulsions. Diluents for the aqueous solution or suspension contain, for example, distilled water for injection, physiological saline and Ringer's solution. Diluents for the nonaqueous solution and suspension contain, for example, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol and polysorbates. The composition may contain other additives such as preservatives, wetting agents, emulsifying agents, and dispersing agents. These are sterilized by filtration through, eg. a bacteria-preventing filter, compounding with a sterilizer, gas sterilization or radiation sterilization. These can be prepared by producing a sterile solid composition and dissolving it into sterilized water or a sterilized solvent for injection before use. The invention will be illustrated with reference to the following examples and accompanying drawings, in which: Fig. 1 shows change of body temperature before and after administration of a test drug 24, (13,14-dihydro-15-keto-PGE₂ ethyl ester) to a rat subjected to bloodletting. Fig. 2 shows change of body temperature before and after administration of a test drug 8, (13,14-dihydro-6,15-diketo-PGE₁ ethyl ester) to a rat subjected to bloodletting. Fig. 3-13 are n.m.r. charts of 13,14-dihydro-15-keto-PGEs of the present invention. Example 1 (fervescence activity by intracerebroventricular injection). Wister male rats (8 weeks old) were used as test animals. Rats were anaesthetized by intraperitoneal injection with 1.25 g/kg of urethane and a stainless guide cannula was inserted into the lateral ventricle for administration of a test drug according to Pellegrino's Rat brain atras. Each test drug was dissolved into an artificial cerebrospinal fluid and 400 ng as drug in 3 µl was injected through the injection cannula for 15 seconds. The artificial cerebrospinal fluid alone was injected as a control. Body temperature was measured continuously at the rectum. Increase in body temperature is shown in degrees (°C) from the temperature before administration. The results are shown in Table 1. Test Drug Rising of body temperature 22 +0.7 23 +0.4 24 +0.5 26 +0.1 1 +0.4 2 +0.4 6 +0.8 7 +0.6 8 +0.4 Control 0 Example 2 (fervescence activity by intravenous injection) Test animals were Wister male rats (8 weeks old) weighing 200 ± 10 g. The rats were anaesthetized by intraperitoneal injection of 1.25 g/kg of urethane. Each test drug was dissolved into ethyl alcohol. The ethyl alcohol solution was diluted with Ringer's solution at least 50 times just before use and 1 mg/kg of the each test drug was intravenously administered. Body temperature was measured in the same manner as in Example 1. Ringer's solution containing ethyl alcohol was administered as a control. Rising of body temperature is shown by the rising degree (°C) from the temperature before administration. The results are shown in Table 2. Test Drug Rising of Body Temperature (°C) Test Drug Rising of Body Temperature (°C) 1 0 18 + 0.7 2 + 0.9 19 + 1.0 3 0 20 + 1.3 4 + 0.8 21 + 1.1 5 + 0.4 22 0 6 0 23 + 1.0 7 + 0.8 24 + 0.5 8 + 0.6 25 + 0.2 9 + 0.7 26 + 0.2 10 + 0.2 27 + 0.3 11 + 1.5 28 + 0.4 12 + 0.9 29 + 1.0 13 + 1.1 30 + 1.7 14 + 1.0 31 + 1.0 15 + 0.7 32 + 1.4 16 + 0.8 33 + 0.9 17 + 0.4 34 + 1.0 Test Drug Increase in Body Temperature (°C) Test Drug Increase in Body Temperature (°C) 35 + 1.0 48 + 0.2 36 + 0.6 49 + 0.2 37 + 0.2 50 + 0.2 38 + 0.3 51 + 0.2 39 + 0.9 52 + 0.2 40 + 1.4 53 + 0.5 41 + 0.8 54 + 0.2 42 + 1.4 55 + 0.2 43 + 0.2 56 + 1.0 44 + 0.2 57 0 45 + 2.0 58 + 0.7 46 + 0.6 59 + 1.2 47 + 0.3 control 0 Test drug (Figure number of n.m.r. charts of corresponding compounds are shown in brackets after the compound names respectively.) 1: 13,14-dihydro-15-keto-PGE₁ 2: 13,14-dihydro-15-keto-PGE₁ ethyl ester 3: 13,14-dihydro-15-keto-Δ²-PGE₁ 4: 13,14-dihydro-15-keto-Δ²-PGE₁ methyl ester 5: 13,11-dihydro-15-keto-20-ethyl-PGE₁ methyl ester 6: 13,14-dihydro-6,15-diketo-PGE₁ 7: 13,14-dihydro-6,15-diketo-PGE₁ methyl ester 8: 13,14-dihydro-6,15-diketo-PGE₁ ethyl ester 9: (±) 13,14-dihydro-6,15-diketo-PGE₁ ethyl ester 10: 13,14-dihydro-6,15-diketo-PGE₁ n-butyl ester 11: 13,14-dihydro-6,15-diketo-16R,S-methyl-PGE₁ methyl ester 12: 13.14-dihydro-6,15-diketo-16R,S-methyl-PGE₁ ethyl ester (Fig.3) 13: 13,14-dihydro-6,15-diketo-16,16-dimethyl-PGE₁ ethyl ester 14: 13,14-dihydro-6,15-diketo-16R,S-fluoro-PGE₁ ethyl ester, 15: 13,14-dihydro-6,15-diketo-19-methyl-PGE₁ methyl ester 16: 13,14-dihydro-6,15-diketo-19-methyl-PGE₁ ethyl ester (Fig.4) 17: 13,14-dihydro-6,15-diketo-11-dehydroxy-11R-hydroxymethyl-19-methyl-PGE₁ methyl ester 18: 13,14-dihydro-6,15-diketo-20-methyl-PGE₁ ethyl ester 19: 13,14-dihydro-6,15-diketo-11-dehydroxy-11R-methyl-PGE₁ methyl ester 20: 13,14-dihydro-6,15-diketo-11-dehydroxy-11R-methyl-PGE₁ ethyl ester (Fig.5) 21: 13,14-dihydro-6,15-diketo-16R,S-fluoro-11R-dehydroxy-11R-methyl-PGE₁ ethyl ester (Fig.6) 22: 13,14-dihydro-15-keto-PGE₂ 23: 13,14-dihydro-15-keto-PGE₂ methyl ester 24: 13,14-dihydro-15-keto-PGE₂ ethyl ester (Fig.7) 25: 13,14-dihydro-15-keto-PGE₂ n-propyl ester 26: 13,14-dihydro-15-keto-PGE₂ n-butyl ester 27: 13,14-dihydro-15-keto-PGE₂ benzyl ester 28: 13,14-dihydro-15-keto-PGE₂ hydroxyethyl ester 29: 13,14-dihydro-15-keto-Δ²-PGE₂-methyl ester (Fig.8) 30: 13,14-dihydro-15-keto-3R,S-methyl-PGE₂ methylester 31: 13,14-dihydro-15-keto-3R,S-methyl-PGE₂ ethyl ester (Fig.9) 32: 13,14-dihydro-15-keto-16R,S-methyl-PGE₂ methyl ester 33: 13,14-dihydro-15-keto-16R,S-methyl-PGE₂ ethyl ester (Fig.10) 34: 13,14-dihydro-15-keto-3R,S,16R,S-dimethyl-PGE₂ methyl ester 35: 13,14-dihydro-15-keto-16,16-dimethyl-PGE₂ methyl ester 36: 13,14-dihydro-15-keto-16,16-dimethyl-PGE₂ ethyl ester 37: 13,14-dihydro-15-keto-16R,S-hydroxy-PGE₂ ethyl ester 38: 13,14-dihydro-15-keto-16R,S-fluoro-PGE₂ (tautomeric isomer between carbonyl group at carbon atom of 15-position and hydroxyl group on carbon atom of 11-position is confirmed.) 39: 13,14-dihydro-15-keto-16R,S-fluoro-PGE₂ methyl ester 40: 13,14-dihydro-15-keto-16R,S-fluoro-PGE₂ ethyl ester 41: 13,14-dihydro-15-keto-16R,S-fluoro-20-methyl-PGE₂ methyl ester (Fig.11) 42: 13,14-dihydro-15-keto-16R,S-fluoro-11-dehydroxy-11R-methyl-PGE₂ ethyl ester (Fig.12) 43: 13,14-dihydro-15-keto-11-dehydroxy-11R-methyl-PGE₂ ethyl ester 44: 13,14-dihydro-15-keto-17S-methyl-PGE₂ methyl ester 45: 13,14-dihydro-15-keto-19-methyl-PGE₂ methyl ester 46: 13,14-dihydro-15-keto-19-methyl-PGE₂ ethyl ester 47: 13,14-dihydro-15-keto-20-methoxy-PGE₂ methyl ester 48: 13,14-dihydro-15-keto-20-methoxy-Δ²-PGE₂ methyl ester 49: 13,14-dihydro-15-keto-3R,S-methyl-20-methoxy-PGE₂ methyl ester 50: 13,14-dihydro-15-keto-16,16-dimethyl-20-methoxy-PGE₂ methyl ester 51: 13,14-dihydro-15-keto-20-isopropylidene-PGE₂ 52: 13,14-dihydro-15-keto-20-isopropylidene-PGE₂ methyl ester 53: 13,14-dihydro-15-keto-20-ethyl-PGE₂ methyl ester 54: 13,14-dihydro-15-keto-20-ethyl-PGE₂ ethyl ester 55: 13,14-dihydro-15-keto-20-ethyl-11-dehydroxy-11R-methyl-PGE₂ methyl ester 56: 15-keto-16R,S-fluoro-PGE₂ methyl ester (Fig.13) 57: PGE₁ 58: PGE₂ 59: PGE₂ methyl ester As shown in Table 2, 15-keto-PGEs obviously show fervescence activity even by peripheral administration such as intravenous injection. Example 3 Experiment was carried out in the same manner as in Example 2 except for that test drugs were administered intravenously with a dose of 5 mg/kg. The results are shown in Table 3. Test Drug Increase in body temperature (°C) 25 +1.3 26 +0.9 Example 4 (fervescence (recovery of body temperature) activity at hemorrhage load) Wister male rats (weight: 200g) were subcutaneously injected in the back with 1.5 g/kg of urethane and anaesthetized. Hemorrhage was then induced by withdrawal of blood by puncture of the heart for the total volume of 3 ml equivalent to 1.5% of the body weight. After storage in a room for 60 minutes, the rats were administered intraveously with test solutions prepared by dissolving test drugs into Ringer's solution so as to administer the rat a dose of 0.5 or 1 mg/kg. Change in body temperature was observed. Ringer's solution was administered as a control. The results are shown in Table 4 and Figs. 1 and 2. (Fervescence Activity on the Rat subjected to Hemorrhage) Test Drug Rising of Body Temperature (°C) 0.5 mg/kg 1 mg/kg 8 +0.7 +0.8 16 +0.4 +0.6 18 +0.4 +0.8 20 +0.5 +0.8 24 +0.8 +1.1 Control 0 Fig. 1 shows change of body temperature before and after administration of a test drug 24, (13,14-dihydro-15-keto-PGE₂ ethyl ester) to a rat loaded with hemorrhage. Fig. 2 shows change of body temperature before and after administration of a test drug 8, (13,14-dihydro-6,15-diketo-PGE₁ ethyl ester) to a rat subjected to hemorrhage. In the figures, (1) (2) and (3) correspond to the results of administration of doses 1 mg/kg, 0.5 mg/kg and Ringer's solution alone, respectively. As shown in Table 4 and Figs. 1 and 2, the group of rats administered with the 15-keto-PGEs of this invention show a dose response fervescence. Body temperature continued to fall after the administration in the group administered with Ringer's solutions. The compound of this invention is useful as drug for recovering body temperature from hypothermia caused by serious bleeding and surgery. The above results prove the fervescence activity of the compound in animals suffering from low body temperature (33 °C) or being unable to maintain the normal body temperature through bleeding, namely, out of homeostasis. Example 5 (Sedation Activity) A 19-methyl type compound having strong fervescence activity was compared with PGE₂ methyl ester in sedation activity. A hybrid adult dog was held in a dog holder and intravenously administered with a test drug dissolved in Ringer's solutions at the forefoot. Sedation activity was judged as follows: Sedation Degree 1: Disappearance of body movement 2: Closing of the eyes 3: Leaning on the holding belt Test Drug Dose mg/kg Increase in body Temperature (°C) Sedation Degree 1 2 3 45 0.5 0.5 - - - 15 0.5 1.2 - - - 16 0.5 1.1 - - - 59 0.01 0.4 + + + As shown by the results in Table 5, the test drugs of this invention show no sedation activity and PGE₂ methyl ester shows clear sedation activity. EXAMPLE 6 (acute toxicity) Acute toxicity (LD₅₀) of the test drugs was estimated on Slc-ddY female mice (5-weeks old) by an intravenous injection. Results are shown in Table 6. test drug LD₅₀ mg/kg 2 >1000 16 > 300 23 >1000 24 1000 The 15-keto-PGEs of this invention have fervescense activity and the compound in the ester form shows the activity by peripheral administration such as intravenous injection or oral administration in the same manner as by intracerebroventricular injection. The 15-keto-PGEs also have fervescence activity in an animal out of homeostasis. Accordingly, the 15-keto-PGEs of this invention are useful as a drugs for recovering from hypothermia occurred after hypothermic operation such as surgical operation, hypothermia accompanied with a decline of basal metabolism ratio by such as thyroid hormone hyposecretion, hypothermia by disorder of the brain, hypothermia caused by serious bleeding and disorder of consciousness, hypothermia caused by lowering of the surrounding temperature, hypothermia caused by heatloss from the surface of the body by such as sweating and vasodilation, hypothermia and asphyxiation, and also useful as a drug for increasing body temperature, which has fallen through shock to restore various body mechanisms lost through shock and improve the homeostasis maintaining ability. Additionally, they are useful as a drugs for preventing the above hypothermias.

Claims: Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE The use of 15-keto-PGEs for the manufacture of a medicament for increasing body temperature. The use as claimed in claim 1 wherein the medicament is for recovering body temperature. The use as claimed in claim 1 wherein the medicament is for the treatment of hypothermia. The use as claimed in any one of Claims 1 to 3, in which 15-keto-PGEs are represented by the following formula: wherein R is a hydroxyl group, a hydroxyalkyl group, or an alkyl group; Y is a saturated or an unsaturated hydrocarbon moiety having 2 - 6 carbon atoms wherein a portion of carbon atoms constituting the hydrocarbon moiety may be carbonyl or the hydrcarbon moiety may be substituted with atoms or groups selected from halogen atoms, an alkyl group and a hydroxy group; Z is a saturated or an unsaturated hydrocarbon moiety having 1 - 10 carbon atoms which may constitute a ring or the hydrocarbon moiety may be substituted with atoms or groups selected from halogen atoms, an alkyl group, an alkoxy group, a hydroxy group, atoms or groups; a phenyl group, and a phenoxy group; and physiologically acceptable salts or esters thereof. The use as claimed in Claim 4, in which 15-keto-PGEs are esters of 15-keto-PGEs. The use as claimed in Claim 4, in which Z represents a formula: -CH₂CH₂CH₂CH(R₁)(R₂): wherein R₁ is a hydrogen atom or a methyl group, and R₂ is a methyl group, an ethyl group or a propyl group. The use as claimed in Claim 4, wherein Z is a fluoroalkyl group. The use as claimed in any one of Claims 1 to 3, wherein 15-keto-PGEs are 13,14-dihydro-15-keto-PGEs. The use as claimed in any one of Claims 1 to 3, wherein 15-keto-PGEs are 13,14-dihydro-15-keto-19-methyl-PGEs. The use as claimed in any one of Claims 1 to 3, wherein 15-keto-PGEs are 13,14-dihydro-15-keto-16R,S-fluoro-PGEs. The use as claimed in any one of Claims 1 to 3, wherein 15-keto-PGEs are 13,14-dihydro-15-keto-16R,S-fluoro-11-dehydroxy-11R-methyl-PGEs. The use as claimed in any one of Claims 1 to 3, wherein 15-keto-PGEs are 13,14-dihydro-15-keto-3R,S-methyl-PGEs. The use as claimed in any one of Claims 1 to 3, wherein 15-keto-PGEs are 13,14-dihydro-15-keto-16R,S-methyl-PGES. The use as claimed in any one of Claims 1 to 3, wherein 15-keto-PGEs are 13,14-dihydro-6,15-diketo PGE 1s . Claims for the following Contracting States : ES, GR A method of producing a fervescence composition comprising admixing a 15-keto-PGE and a pharmaceutically acceptable excipient. A method of producing a medicament for recovering body temperature comprising admixing a 15-keto-PGE and a pharmaceutically acceptable excipient. A method of producing a medicament for the treatment of hypothermia comprising admixing a 15-keto-PGE and a pharmaceutically acceptable excipient. A method as claimed in any one of Claims 1 to 3, in which the 15-keto-PGE is represented by the following formula: wherein R is a hydroxyl group, a hydroxyalkyl group, or an alkyl group; Y is a saturated or an unsaturated hydrocarbon moiety having 2 - 6 carbon atoms wherein a portion of carbon atoms constituting the hydrocarbon moiety may be,carbonyl or the hydrocarbon moiety may be substituted with atoms or groups selected from halogen atoms, an alkyl group and a hydroxy group; Z is a saturated or an unsaturated hydrocarbon moiety having 1 - 10 carbon atoms which may constitute a ring or the hydrocarbon moiety may be substituted with atoms or groups selected from halogen atoms, an alkyl group, an alkoxy group, a hydroxy group, a phenyl group, and a phenoxy group; and physiologically acceptable salts or esters thereof. A method as claimed in Claim 4, in which the 15-keto-PGE is an ester of 15-keto-PGEs. A method as claimed in Claim 4, in which Z represents a formula: -CH₂CH₂CH₂CH(R₁)(R₂): wherein R₁ is a hydrogen atom or a methyl group, and R₂ is a methyl group, an ethyl group or a propyl group. A method as claimed in Claim 4, wherein Z is a fluoroalkyl group. A method as claimed in any one of Claims 1 to 3, wherein 15-keto-PGEs are 13,14-dihydro-15-keto-PGEs. A method as claimed in any one of Claims 1 to 3, wherein the 15-keto-PGE is a 13,14-dihydro-15-keto-19-methyl-PGE. A method as claimed in any one of Claims 1 to 3, wherein the 15-keto-PGE is a 13,14-dihydro-15-keto-16R,S-fluoro-PGE. A method as claimed in any one of Claims 1 to 3 wherein the 15-keto-PGE is a 13,14-dihydro-15-keto-16R,S-fluoro-11-dehydroxy-11R=methyl-PGE. A method as claimed in any one of Claims 1 to 3, wherein the 15-keto-PGE is a 13,14-dihydro-15-keto-3R,S-methyl-PGE. A method as claimed in any one of Claims 1 to 3, wherein the 15-keto-PGE is a 13,14-dihydro-15-keto-16R,S-methyl-PGE. A method as claimed in any one of Claims 1 to 3, wherein the 15-keto-PGE is a 13,14-dihydro-6,15-diketo PGE₁.

Inventors: ODA, TOMIO, UENO, RYUJI, UENO, RYUZO
Applicants: KABUSHIKI KAISHA UENO SEIYAKU OYO KENKYUJO
Application year: 1988
Main classification: A61K31
IPC codes: A61K31